EUVIMEDEUVIMED entdecken
Crossref

Modified CD40L‐Activated B‐Cell Proliferation Model for Validating the Suppressive Activity of CD40‐CD154 Pathway Inhibitors

Man Zhang, Hao Feng, Yahui Huang, Tianyi Hu, Jiaxiang Du, Yong Wang, Song Chen, Dengke Pan, Lan Zhu, Gang Chen

Xenotransplantation · 2025

DOI: 10.1111/xen.70029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Xenotransplantation, 2025. Verfasst von Man Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ T…. Hauptthemen laut MEDLINE: B-Lymphocytes, CD40 Antigens, Cell Proliferation, CD40 Ligand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Key Research and Development Program, Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation, Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD40‐CD154 pathway inhibitors are considered indispensable immunosuppressive drugs in xenotransplantation. At present, novel anti‐CD154 and anti‐CD40 monoclonal antibodies (mAbs) are continuously being developed. It is important to establish a simple and efficient in vitro method to evaluate the effectiveness of these therapeutic mAbs.

Methods

A modified CD40L‐activated B‐cell proliferation model was established using irradiated NIH/3T3 cells transfected with human CD40 ligand (hCD40L‐NIH/3T3) as stimulator cells and human or rhesus monkey peripheral blood mononuclear cells (PBMCs) as responder cells. After 8 days of culture, B‐cell proliferation was detected by flow cytometry. Various concentrations of anti‐CD40 or anti‐CD154 mAbs were added to the co‐culture system as an intervention. The inhibitory effects of anti‐CD154 and anti‐CD40 mAbs on the proliferation of B cells from humans and rhesus monkeys were studied and compared.

Results

After 8 days of co‐culture, the proliferation rate of B cells in both human and rhesus monkey PBMCs was more than 80%, and the expression of MHC‐II and the co‐stimulatory molecules CD80, CD86, and CD40 on B cells was significantly up‐regulated. All three anti‐CD154 mAbs showed a similar strong inhibitory effect on human B‐cell proliferation, but the inhibitory effect on the proliferation of rhesus monkey B cells was weaker than that on human B cells, which showed a typical dose‐dependent inhibition. The three anti‐CD40 mAbs from different sources had different effects. One mAbs potently inhibited both human and monkey B‐cell proliferation, whereas the other two mAbs exhibited strong or moderate inhibitory effects on human B‐cell proliferation but had little inhibitory effect on monkey B‐cell proliferation.

Conclusion

We have successfully established a modified CD40L‐activated B‐cell proliferation model for the in vitro evaluation of CD40‐CD154 pathway inhibitors, which may provide important evidence for the selection of appropriate therapeutic antibodies and their dose determination for xenotransplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-LymphocytesCD40 AntigensCell ProliferationCD40 LigandImmunosuppressive AgentsAnimalsHumansMacaca mulattaMiceTransplantation, HeterologousCoculture TechniquesAntibodies, MonoclonalLymphocyte Activation

Stichwörter der Autor:innen

B‐cell proliferationCD40‐CD40L pathwayanti‐CD154 monoclonal antibodyanti‐CD40 monoclonal antibodyxenotransplantation

Substanzen

CD40 AntigensCD40 LigandAntibodies, MonoclonalImmunosuppressive Agents

Autor:innen und Institutionen

  • Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Tra…
  • Chengdu Clonorgan Biotechnology Co., Ltd, Chengdu, China.

Förderung

  • National Key Research and Development Program
  • Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation
  • Natural Science Foundation of Hubei Province
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, M., Feng, H., Huang, Y., Hu, T., Du, J., Wang, Y., Chen, S., Pan, D., Zhu, L., & Chen, G. (2025). Modified CD40L‐Activated B‐Cell Proliferation Model for Validating the Suppressive Activity of CD40‐CD154 Pathway Inhibitors. Xenotransplantation. https://doi.org/10.1111/xen.70029

Vancouver

Zhang M, Feng H, Huang Y, Hu T, Du J, Wang Y, et al. Modified CD40L‐Activated B‐Cell Proliferation Model for Validating the Suppressive Activity of CD40‐CD154 Pathway Inhibitors. Xenotransplantation. 2025. doi:10.1111/xen.70029

BibTeX
@article{Zhang2025,
  author = {Zhang, Man and Feng, Hao and Huang, Yahui and Hu, Tianyi and Du, Jiaxiang and Wang, Yong and Chen, Song and Pan, Dengke and Zhu, Lan and Chen, Gang},
  title = {Modified CD40L‐Activated B‐Cell Proliferation Model for Validating the Suppressive Activity of CD40‐CD154 Pathway Inhibitors},
  journal = {Xenotransplantation},
  year = {2025},
  doi = {10.1111/xen.70029}
}
Kostenlos starten →